NasdaqGS - Nasdaq Real Time Price USD

Dyne Therapeutics, Inc. (DYN)

Compare
31.94 -14.15 (-30.70%)
At close: 4:00 PM EDT
32.11 +0.17 (+0.53%)
After hours: 7:44 PM EDT
Loading Chart for DYN
DELL
  • Previous Close 46.09
  • Open 27.84
  • Bid 23.56 x 200
  • Ask 37.32 x 200
  • Day's Range 23.55 - 33.00
  • 52 Week Range 6.40 - 47.45
  • Volume 13,717,675
  • Avg. Volume 1,006,948
  • Market Cap (intraday) 3.207B
  • Beta (5Y Monthly) 1.07
  • PE Ratio (TTM) --
  • EPS (TTM) -3.58
  • Earnings Date Oct 28, 2024 - Nov 1, 2024
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 53.22

Dyne Therapeutics, Inc., a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.

www.dyne-tx.com

152

Full Time Employees

December 31

Fiscal Year Ends

Recent News: DYN

View More

Performance Overview: DYN

Trailing total returns as of 9/3/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

DYN
140.15%
S&P 500
15.91%

1-Year Return

DYN
171.37%
S&P 500
22.44%

3-Year Return

DYN
91.26%
S&P 500
21.86%

5-Year Return

DYN
41.39%
S&P 500
64.70%

Compare To: DYN

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: DYN

View More

Valuation Measures

Annual
As of 8/30/2024
  • Market Cap

    4.63B

  • Enterprise Value

    3.87B

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    --

  • Price/Book (mrq)

    5.97

  • Enterprise Value/Revenue

    --

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -31.45%

  • Return on Equity (ttm)

    -52.46%

  • Revenue (ttm)

    --

  • Net Income Avi to Common (ttm)

    -257.6M

  • Diluted EPS (ttm)

    -3.58

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    778.84M

  • Total Debt/Equity (mrq)

    3.32%

  • Levered Free Cash Flow (ttm)

    -130.44M

Research Analysis: DYN

View More

Company Insights: DYN

Research Reports: DYN

View More

People Also Watch